Source comparison
Hexarelin vs Tesamorelin + Ipamorelin Blend: Research Application Comparison
Peak GH Amplitude 12–18× baseline (acute phase) 6–9× baseline (sustained) Hexarelin wins on acute magnitude, but blend maintains consistency across extended timelines Receptor Durability 40–60% efficacy loss by week 10 No tachyphylaxis through 24 weeks Blend s
This comparison does not assign a generated winner or score.
- Peak GH Amplitude
- 12–18× baseline (acute phase)
- 6–9× baseline (sustained)
- Hexarelin wins on acute magnitude, but blend maintains consistency across extended timelines
- Receptor Durability
- 40–60% efficacy loss by week 10
- No tachyphylaxis through 24 weeks
- Blend superior for protocols >12 weeks
- Cardiovascular Risk
- Elevated heart rate, myocardial stress, dose-dependent cardiotoxicity
- Minimal cardiovascular effects at therapeutic doses
- Blend far safer in subjects with metabolic or cardiac considerations
- Cortisol Elevation
- 25–40% increase at research doses
- No measurable cortisol spike (ipamorelin selectivity)
- Blend eliminates confounding stress hormone variable
- Dosing Complexity
- 100–200mcg, 1–2× daily; requires escalation after week 8
- Tesamorelin 1–2mg daily + ipamorelin 200–300mcg, 1–2× daily; stable dosing
- Blend offers simpler protocol management over time
- Cost per Research Cycle
- $180–$320 per 16-week cycle
- $280–$450 per 16-week cycle
- Hexarelin cheaper upfront, but dose escalation narrows gap by week 12
- Ideal Research Application
- Short-duration (4–8 week) acute GH response studies
- Extended metabolic, body composition, or tissue repair studies (12–24 weeks)
- Match peptide to study duration and endpoint variables